<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03938649</url>
  </required_header>
  <id_info>
    <org_study_id>PST008</org_study_id>
    <nct_id>NCT03938649</nct_id>
  </id_info>
  <brief_title>SRAM study_Postate Cancer</brief_title>
  <official_title>Randomized Phase II Study of Combination Androgen Deprivation Therapy (ADT) and Radiotherapy in High Risk Prostate Cancer: Stereotactic Body Radiotherapy vs conventionAl IMRT to Prostate and Pelvic Nodes (SRAM Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CCTU</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese University of Hong Kong</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 2 randomized study for High risk localized prostate cancer (T3 to T4 disease&#xD;
      and/or PSA &gt; 20 and/or Gleason score ≥ 8) without evidence of distant and nodal metastasis.&#xD;
&#xD;
      Patient will be randomized to:Arm 1&#xD;
&#xD;
        -  Conventional IMRT RapidArc IMRT to prostate and pelvic nodes. 76Gy to prostate, 70Gy to&#xD;
           proximal 2/3 of seminal vesicles, and 50Gy to pelvic nodes (up to bifurcation of common&#xD;
           iliac nodes).&#xD;
&#xD;
        -  38 fractions of daily treatment, Monday to Friday&#xD;
&#xD;
      or Arm 2&#xD;
&#xD;
      SBRT&#xD;
&#xD;
        -  RapidArc IMRT to prostate and pelvic nodes. 40Gy to prostate, 36.25Gy to proximal 2/3 of&#xD;
           seminal vesicles, and 25Gy to pelvic nodes (up to bifurcation of common iliac nodes)&#xD;
&#xD;
        -  5 fractions of weekly treatment. Once fraction per week. All patients will be given&#xD;
           neoadjuvant and adjuvant androgen deprivation therapy (detail as below)&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 15, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To compare acute toxicities between SBRT and conventional IMRT</measure>
    <time_frame>4 years</time_frame>
    <description>Toxicities will be assessed by AE CTC version 4 between 2 treatment arms</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To compare health-related quality of life (HRQOL) between SBRT and conventional IMRT</measure>
    <time_frame>4 years</time_frame>
    <description>Questionnaire EPIC will be used at pre-treatment, during treatment and at 3, 6, 9, 12, 18 and 24 months post treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To compare the biochemical-failure free survival at 5 years</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To compare the progression-free survival at 5 years</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To compare the overall survival at 5 years</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To compare the late toxicities between 2 treatment arms</measure>
    <time_frame>5 years</time_frame>
    <description>Toxicities will be assessed by AE CTC version 4 between 2 treatment arms</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Advanced Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Conventional IMRT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RapidArc IMRT to prostate and pelvic nodes. 76Gy to prostate, 70Gy to proximal 2/3 of seminal vesicles, and 50Gy to pelvic nodes (up to bifurcation of common iliac nodes).&#xD;
38 fractions of daily treatment, Monday to Friday</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SBRT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RapidArc IMRT to prostate and pelvic nodes. 40Gy to prostate, 36.25Gy to proximal 2/3 of seminal vesicles, and 25Gy to pelvic nodes (up to bifurcation of common iliac nodes)&#xD;
5 fractions of weekly treatment. Once fraction per week.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Conventional IMRT</intervention_name>
    <description>RapidArc IMRT to prostate and pelvic nodes. 76Gy to prostate, 70Gy to proximal 2/3 of seminal vesicles, and 50Gy to pelvic nodes (up to bifurcation of common iliac nodes).&#xD;
38 fractions of daily treatment, Monday to Friday.&#xD;
All patients will be given neoadjuvant and adjuvant androgen deprivation therapy.</description>
    <arm_group_label>Conventional IMRT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SBRT</intervention_name>
    <description>RapidArc IMRT to prostate and pelvic nodes. 40Gy to prostate, 36.25Gy to proximal 2/3 of seminal vesicles, and 25Gy to pelvic nodes (up to bifurcation of common iliac nodes) 5 fractions of weekly treatment. Once fraction per week. All patients will be given neoadjuvant and adjuvant androgen deprivation therapy.</description>
    <arm_group_label>SBRT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histological confirmation of prostate adenocarcinoma&#xD;
&#xD;
          -  High risk prostate cancer patients (i.e. T3 to T4 disease and/or PSA &gt; 20 and/or&#xD;
             Gleason score ≥ 8)&#xD;
&#xD;
          -  ECOG performance score 0-1&#xD;
&#xD;
          -  Age ≥ 18&#xD;
&#xD;
          -  History/physical examination within 2 weeks prior to registration&#xD;
&#xD;
          -  Able to sign informed-consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with active cancer other than prostate cancer and non-melanoma skin cancer.&#xD;
&#xD;
          -  Evidence of distant metastases&#xD;
&#xD;
          -  Regional lymph node involvement&#xD;
&#xD;
          -  Previous radical surgery (prostatectomy), cryosurgery, or HIFU for prostate cancer&#xD;
&#xD;
          -  Previous pelvic irradiation, prostate brachytherapy, or bilateral orchiectomy&#xD;
&#xD;
          -  Previous hormonal therapy, such as LHRH agonists (e.g., goserelin, leuprolide) or LHRH&#xD;
             antagonists (e.g., degarelix), anti-androgens (e.g., flutamide, bicalutamide),&#xD;
             estrogens (e.g. DES), or surgical castration (orchiectomy)&#xD;
&#xD;
          -  Unstable angina and/or congestive heart failure requiring hospitalization, transmural&#xD;
             myocardial infarction within the last 6 months, acute bacterial or fungal infection&#xD;
             requiring intravenous antibiotics, chronic obstructive pulmonary disease exacerbation&#xD;
             or other respiratory illness requiring hospitalization or precluding study therapy at&#xD;
             the time of registration&#xD;
&#xD;
          -  Patients who have received prior chemotherapy.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Darren MC POON, FHKCR</last_name>
    <phone>3505 2128</phone>
    <email>mc_poon@clo.cuhk.edu.hk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jane KOH, RN</last_name>
    <phone>3505 1142</phone>
    <email>jane@clo.cuhk.edu.hk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Clinical Oncology, Prince of Wales Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Darren MC POON, FHKCR</last_name>
      <phone>35052128</phone>
      <email>mc_poon@clo.cuhk.edu.hk</email>
    </contact>
    <contact_backup>
      <last_name>Jane Koh, RN</last_name>
      <phone>35051142</phone>
      <email>jane@clo.cuhk.edu.hk</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Hong Kong</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>April 18, 2019</study_first_submitted>
  <study_first_submitted_qc>May 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 6, 2019</study_first_posted>
  <last_update_submitted>July 26, 2021</last_update_submitted>
  <last_update_submitted_qc>July 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Chinese University of Hong Kong</investigator_affiliation>
    <investigator_full_name>CCTU</investigator_full_name>
    <investigator_title>Comprehensive Clinical Trial Unit</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

